Replies to post #75491 on Biotech Values

[DewDiligence]

Clevudine's different MoA makes it a good candidate for combo therapy, should it be adopted in HBV.

I think VRUS’ claim that Clevudine has “a different MoA” from other HBV nukes is partly spin. The more relevant impetus for combination therapy including Clevudine, IMO, is the comment in the bottom paragraph of #msg-36811361.